

The 20th JFCR-ISCC

New Antitumor Agents under Development in the US, Europe and Japan



2015

December 9, (Wed)

13:00 - 18:20

December 10, (Thu)

9:00 - 17:20

Miraikan

National Museum of
Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Contact:
Cancer Chemotherapy Center,
Japanese Foundation for Cancer Research
jfc-r-iscc@ml.jfcr.or.jp

<http://iscc.umin.jp/>

Dec. 9

A new era of immuno-oncology

13:10-

Alan J. Korman *BMS*

Antitumor activity of immunomodulatory antibodies
– anti-CTLA-4 and anti-PD-1

Keiya Ozawa *Univ. of Tokyo*

CD19-specific CAR (chimeric antigen receptor)-expressing
T cell gene therapy for B cell malignancies

Timothy A. Chan *MSKCC*

Genomic landscapes and response to immune-based therapy

Toward precision cancer medicine

15:25 -

Lillian Siu *Princess Margaret Cancer Ctr.*

Genomic based clinical trials – now and next generation

Katsuya Tsuchihara *National Cancer Ctr.*

A nation-wide genome prescreening program stratifying
lung and gastrointestinal cancer patients, SCRUM-Japan

Stefan Sleijfer *Erasmus Medical Ctr. Cancer Inst.*

Liquid biopsies; potential valuable tool in
drug development studies

Poster Session

17:20 -

Dec.10

Targeting epigenetics for cancer therapy

9:00 -

Yutaka Kondo *Nagoya City Univ.*

Clinical implications of epigenetic alterations in
human tumors

Tom Heightman *Astex Pharmaceuticals*

Discovery and development of SGI-110 (guadecitabine),
a second generation hypomethylating agent with clinical
efficacy

Poster Discussion Session 10:35-

Luncheon Seminar

12:00-

Teiji Takechi *Taiho Pharmaceutical Co., Ltd.*

TAS-102, a novel oral antitumor drug consisting of
trifluridine and tipiracil hydrochloride

Meet-the-Expert Seminar 13:00-

Alice Shaw *MGH Cancer Ctr.*

Next generation ALK/ROS1 inhibitors in NSCLC

Molecular mechanisms of drug resistance and rational drug combinations

14:10-

Hiromichi Ebi *Kanazawa Univ.*

Combinatorial approach targeting KRAS mutant cancers

Ryan B. Corcoran *MGH Cancer Ctr.*

Combination therapy for RAS and RAF mutant cancers

Anthony W. Tolcher *START*

Antitumor activity in RAS-driven tumors by blocking AKT
and MEK

New targets and drugs under clinical or preclinical investigations

16:05-

Tesshi Yamada *National Cancer Ctr.*

Targeting the Wnt signaling pathway in colorectal cancer

Mikihiko Naito *National Inst. of Health Sci.*

Protein knockdown by SNIPER compounds, inducers
for target protein-selective degradation